The Journal of Headache and Pain

Featured Articles: April, 2022

The Global Campaign turns 18: a brief review of its activities and achievements

^{Steiner, T.J., Birbeck, G.L., Jensen, R.H. et al. The Global Campaign turns 18: a brief review of its activities and achievements. J Headache Pain 23, 49 (2022).}

The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates

^{Stovner, L.J., Hagen, K., Linde, M. et al. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23, 34 (2022).}

Visual Abstracts

The Journal of Headache and Pain encourages authors to submit a visual abstract along with their manuscripts.

As an author submitting at The Journal of Headache and Pain you are entitled to a 20% discount on professionally produced visual abstracts. Click here to find out more about the service, and your discount will be automatically applied when using this link.

Aims and scope

The Journal of Headache and Pain is a peer-reviewed open access journal specifically dedicated to researchers involved in all aspects of headache and related pain syndromes, including epidemiology, public health, basic science, translational medicine, clinical trials and real-world data. With a multidisciplinary perspective, The Journal of Headache and Pain covers headache medicine and related pain syndromes in all medical disciplines and particularly encourages clinical, translational and basic science submissions in the areas of pain management, genetics, neurology and internal medicine. Read more.

Articles

Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor

Authors: Sanne Hage La Cour, Kiki Juhler, Lisette J. A. Kogelman, Jes Olesen, Dan Arne Klærke, David Møbjerg Kristensen and Inger Jansen-Olesen

Content type: Research 26 May 2022
The economic and personal burden of cluster headache: a controlled cross-sectional study

Authors: Anja Sofie Petersen, Nunu Lund, Agneta Snoer, Rigmor Højland Jensen and Mads Barloese

Content type: Research 24 May 2022
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine

Authors: Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson, Oscar Patterson-Lomba, Michael J. Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu and Rajeev Ayyagari

Content type: Research article 16 May 2022
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study

Authors: Hannah Schenk, Dagny Holle, Michael Nsaka, Christoph Kleinschnitz, Martin Glas and Armin Scheffler

Content type: Research 11 May 2022
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States

Authors: Lynda J. Krasenbaum, Vasantha L. Pedarla, Stephen F. Thompson, Krishna Tangirala, Joshua M. Cohen and Maurice T. Driessen

Content type: Research article 4 May 2022

Most recent articles RSS

View all articles

Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis

Authors: David García-Azorín, Thien Phu Do, Andreas R. Gantenbein, Jakob Møller Hansen, Marcio Nattan P. Souza, Mark Obermann, Heiko Pohl, Christoph J. Schankin, Henrik Winther Schytz, Alexandra Sinclair, Guus G. Schoonman and Espen Saxhaug Kristoffersen

Content type: Short report 17 September 2021
Headache characteristics in COVID-19 pandemic-a survey study

Authors: Özge Uygun, Mustafa Ertaş, Esme Ekizoğlu, Hayrunnisa Bolay, Aynur Özge, Elif Kocasoy Orhan, Arif Atahan Çağatay and Betül Baykan

Content type: Research article 13 October 2020
Headache medication and the COVID-19 pandemic

Authors: Antoinette MaassenVanDenBrink, Tessa de Vries and A. H. Jan Danser

Content type: Commentary 25 April 2020
Headache in transient ischemic attacks

Authors: Elena R. Lebedeva, Natalia M. Gurary and Jes Olesen

Content type: Research article 27 July 2018
Headache associated with cough: a review

Authors: Ann Cordenier, Willem De Hertogh, Jacques De Keyser and Jan Versijpt

Content type: Review article 20 May 2013

Most accessed articles RSS

View all articles

_{Consensus article | 16 January 2019}
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
_{Simona Sacco, Lars Bendtsen, Messoud Ashina, Uwe Reuter, Gisela Terwindt, Dimos-Dimitrios Mitsikostas and Paolo Martelletti}

^{Consensus article | 21 May 2019}
Aids to management of headache disorders in primary care (2nd edition)
_{on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache
T. J. Steiner, R. Jensen, Z. Katsarava, M. Linde, E. A. MacGregor, V. Osipova, K. Paemeleire, J. Olesen, M. Peters & P. Martelletti}

_{Review article | 25 April 2019}
A narrative review on the burden of migraine: when the burden is the impact on people’s life
_{Matilde Leonardi & Alberto Raggi}

_{Research article | 07 April 2020}
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
_{Raffaele Ornello, Alfonsina Casalena, Ilaria Frattale, Amleto Gabriele, Giannapia Affaitati, Maria Adele Giamberardino, Maurizio Assetta, Maurizio Maddestra, Fabio Marzoli, Stefano Viola, Davide Cerone, Carmine Marini, Francesca Pistoia & Simona Sacco}

_{Review article | 09 May 2019}
Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications
_{Thomas Dresler, Salvatore Caratozzolo, Kaat Guldolf, Jana-Isabel Huhn, Carmela Loiacono, Triinu Niiberg-Pikksööt, Marta Puma, Giorgia Sforza, Anna Tobia, Raffaele Ornello & Gianluca Serafini on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)}

_{Review article | 13 February 2020}
Gut-brain Axis and migraine headache: a comprehensive review
_{Mahsa Arzani, Soodeh Razeghi Jahromi, Zeinab Ghorbani, Fahimeh Vahabizad, Paolo Martelletti, Amir Ghaemi, Simona Sacco & Mansoureh Togha On behalf of the School of Advanced Studies of the European Headache Federation (EHF-SAS)}

_{Review article | 30 August 2019}
Current and emerging evidence-based treatment options in chronic migraine: a narrative review
_{Elio Clemente Agostoni, Piero Barbanti, Paolo Calabresi, Bruno Colombo, Pietro Cortelli, Fabio Frediani, Pietrangelo Geppetti, Licia Grazzi, Massimo Leone, Paolo Martelletti, Luigi Alberto Pini, Maria Pia Prudenzano, Paola Sarchielli, Gioacchino Tedeschi, Antonio Russo & The Italian chronic migraine group}

_{Editorial | 02 December 2020}
Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019
_{T. J. Steiner, L. J. Stovner, R. Jensen, D. Uluduz & Z. Katsarava on behalf of Lifting The Burden: the Global Campaign against Headache}

_{Review article | 17 April 2019}
Therapeutic novelties in migraine: new drugs, new hope?
_{Thien Phu Do, Song Guo & Messoud Ashina}

_{Research article | 29 July 2020}
Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study
_{Javier Trigo, David García-Azorín, Álvaro Planchuelo-Gómez, Enrique Martínez-Pías, Blanca Talavera, Isabel Hernández-Pérez, Gonzalo Valle-Peñacoba, Paula Simón-Campo, Mercedes de Lera, Alba Chavarría-Miranda, Cristina López-Sanz, María Gutiérrez-Sánchez, Elena Martínez-Velasco, María Pedraza, Álvaro Sierra, Beatriz Gómez-Vicente, Juan Francisco Arenillas & Ángel L. Guerrero}

_{Research article | 01 June 2020}
A prospective real-world analysis of erenumab in refractory chronic migraine
_{Giorgio Lambru, Bethany Hill, Madeleine Murphy, Ivona Tylova & Anna P. Andreou}

_{Publication years: 2019-2020
Source: Web of Science, data collected: February 2022}

Change to the journal’s peer review policy!

The Journal New Content Item (2) of Headache and Pain moves to transparent peer review (TPR).

Under TPR, the journal now publishes all reviewer reports along with the accepted articles under a Creative Commons Attribution License 4.0 but signing of reviewer reports will be optional.

The benefit of transparent peer review is that it increases transparency. In addition, published reports can serve an educational purpose in helping facilitate training and research into peer review.

As a publisher we are firmly committed to the principles of, and move towards open research and science. This transition is reflective not only of our wider vision to support openness and transparency in peer review, a fundamental value at Springer Nature, but also ensuring that our mission and policies best align with the needs and requirements of the research community to support their development and engagement with the journals. Read more about the journal’s peer review policy here.

Recent blogs

Headache after vaccination against COVID-19

01 April 2022
A questionnaire to measure the impact of cluster headaches

17 March 2022
Migraine food triggers and the vicious cycle of painkillers

14 March 2022

Editorial Office

Editor in Chief (Founding)
Paolo Martelletti, MD,
Department of Clinical and Molecular Medicine
Sapienza University of Rome
Via di Grottarossa 1035
I-00189 Rome, Italy
Tel.: +39-06-33775111
Fax: +39-06-33775110
E-mail: paolo.martelletti@uniroma1.it

Call for papers

Real-world evidence of emerging therapies in headache

New Content Item Edited by: Shuu-Jiun Wang and Michel Lanteri-Minet

The aim of this thematic series is to collect high quality real-world data within the headache field. Read more about the scope of the series and contribute with your own research and review articles.

Molecular interactions in migraine

Edit New Content Item ed by Rashid Giniatullin

The aim of this thematic series is to highlight the complexity of molecular mechanisms underlying different types of migraine.

Article collections

Click here to see the article collections and thematic series that the journal has published in recent years.

Headache after vaccination against COVID

New Content Item (2)

Headache is one of the most common adverse side effects of the COVID-19 vaccines. A recent systematic literature review with meta-analysi s, by Dr. Matteo Castaldo et al., assesses the pooled incidence of post-vaccine headache (both after first and second dose). In a blog, authors Dr. Marta Waliszewska-Prosół and Dr. Matteo Castaldo discuss their findings.

Cluster Headache Awareness day! (March 21, 2022)

New Content Item (2) In a blog for Cluster Headache Awareness day, Ruth Ruscheweyh (in the picture) and Katharina Kamm introduce the Cluster Headache Impact Questionnaire (CHIQ) which aims to improve clinical care for cluster headache patients and promote cluster headache research.

Editorial Board spotlight

Prof. Faisal Mohammad Amin is a neurologist and associate professor at the Danish Headache Center. His research focuses on migraine pathophysiology, headache imaging and CGRP mAbs. Moreover, Prof. Amin is the current president of Danish Headache Society, where he has special focus on educational activities.

Q&A with Authors

Click here to see Q&As with the authors of the journal's most highly viewed articles!

European Headache Federation School of Advanced Studies

The European Headache Federation School of Advanced Studies (EHF-SAS) aims to support headache science and offers young EU scientists high quality educational activities to enhance their critical spirit and skills to face headache medicine from a multidisciplinary perspective.

The EHF-SAS covers the richness and diversity of headache medicine fields, including basic science, clinical science, and diagnostic science, and places an emphasis on collaborative projects. The European Headache Federation will support its fellows’ activities allowing them to independently build their own plan sided by the EHF-SAS Scientific Committee.